TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02349243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: 200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
Study: NCT02866045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided fine needle biopsy
Description: EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single incision needle knife biopsy
Description: For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
Study: NCT02589483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The rectal anastomosis will be reinforced with HemoPatch.
Description: Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: The rectal anastomosis reinforced with Hemopatch
Study: NCT01440673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 80 mg, Aprepitant 125 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 80 mg, Aprepitant 125 mg
Study: NCT02573233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893/REGN668
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate and salmeterol
Description: Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate and salmeterol
Description: Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: budesonide and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mometasone furoate and formoterol
Description: Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Study: NCT03724617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells combined with collagen scaffold
Description: 3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
Study: NCT00925691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV lead
Description: The RV lead is implanted at the apex or at the interventricular septum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV lead
Description: The RV lead is implanted at the apex or at the interventricular septum
Study: NCT03850418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
Study: NCT00563368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 15 mg and topiramate 92 mg, po once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 7.5 mg and topiramate 46 mg, po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: topiramate 46 mg, po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: topiramate 92 mg, po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phentermine
Description: phentermine 7.5 mg, po once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phentermine
Description: phentermine 15 mg, po once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VI-0521
Description: placebo, po once daily
Study: NCT04369768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restoration of permanent molars affected with MIH
Description: restore MIH affected molars using direct composite or preformed metal crowns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restoration of permanent molars affected with MIH
Description: restore MIH affected molars using direct composite or preformed metal crowns
Study: NCT03838367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg leronlimab
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 525 mg leronlimab
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg leronlimab
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUC 5 Carboplatin
Description: Carboplatin is an anticancer drug chemotherapy drug.
Study: NCT03259243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
Study: NCT03053557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Coach
Description: Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
Study: NCT01596855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: TIW dosing, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: TIW
Study: NCT03091790

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Mesh
Description: Synthetic mesh used during open ventral hernia repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biologic Mesh
Description: Biologic mesh used during open ventral hernia repair
Study: NCT03170570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
Study: NCT01869634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir with ritonavir and fixed-dose viread+emtricitabine daily
Study: NCT05140772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptiven
Description: IV administration daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: IV administration daily for 7 days
Study: NCT00888706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: The group participated in the usual nursing home activities and routines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Social Activities (ISA)
Description: The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Resistance Training and Walking (PRT/walking)
Description: The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined ISA/PRT/walking
Description: The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
Study: NCT04067089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVR - Transcatheter aortic valve replacement
Description: TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical aortic valve replacement
Description: Surgical aortic valve replacement
Study: NCT02782585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Description: The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical lateral glide
Description: The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervical mobilisation
Description: The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
Study: NCT03759600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule
Study: NCT02655718

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with ACS
Description: Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT05120583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Side kick internal/ external rotation with Pilate's band

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: strength, flexibility
Study: NCT01647698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training task
Description: The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training task
Description: The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-adaptive working memory training task (i.e. an active control task)
Description: Active control task will consist of a non-adaptive working memory task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-adaptive working memory training task (i.e. an active control task)
Description: Active control task will consist of a non-adaptive working memory task.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No training
Description: No training during the experiment.
Study: NCT01396187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 5 mg IV twice a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 25 mg IV twice a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 100 mg IV twice a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 200 mg IV twice a week for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
Study: NCT00399074

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: sulfadoxine pyrimethamine
Description: Monthly SP
Study: NCT00756275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Treatment (NRT)
Description: Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral counseling for smoking cessation
Description: The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral counseling for smoking cessation
Description: The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
Study: NCT02890459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prize incentive - Low
Description: Low expected prize value.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize incentive - Low
Description: Low expected prize value.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize incentive - Low
Description: Low expected prize value.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prize incentive - High
Description: High expected prize value.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize incentive - High
Description: High expected prize value.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize incentive - High
Description: High expected prize value.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escalating payment incentive
Description: The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel Voucher
Description: Travel voucher to assist with linkage to care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Travel Voucher
Description: Travel voucher to assist with linkage to care.
Study: NCT03838367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUC 5 Carboplatin
Description: Carboplatin is an anticancer drug chemotherapy drug.
Study: NCT02890459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Includes HIV viral load and treatment adherence counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Includes HIV viral load and treatment adherence counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Incentive - Prize
Description: Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Aversion - Prize
Description: The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
Study: NCT03838367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUC 5 Carboplatin
Description: Carboplatin is an anticancer drug chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUC 5 Carboplatin
Description: Carboplatin is an anticancer drug chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Tolerated Dose (MTD) of leronlimab
Description: The decision on the MTD will be made following the results obtained from Phase I studies
Study: NCT03962712

Intervention type: OTHER
Intervention: Increase Minimum Wage to $15-an-hour
Description: Increase in minimum wage to $15-an-hour

Intervention type: OTHER
Intervention: No Increase in Minimum Wage
Description: No increase in minimum wage
Study: NCT00093756

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT00436982

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Triathlon total knee system
Description: Orthopaedic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duracon total knee system
Description: Orthopaedic implant
Study: NCT00418717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
Study: NCT02195609

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega-3
Description: 600 mg oral twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soy Isoflavones
Description: 54.4 mg oral twice a day